Association of Abnormal Plasma Bilirubin With Aggressive Hepatocellular Carcinoma Phenotype

详细信息    查看全文

• 作者：Brian I. Carr¹ ; ^{brianicarr@hotmail.com" class="auth_mail} ; Vito Guerra¹ ; Edoardo G. Giannini² ; Fabio Farinati³ ; Francesca Ciccarese⁴ ; Gian Ludovico Rapaccini⁵ ; Maria Di Marco⁶ ; Luisa Benvegnù ; ⁷ ; Marco Zoli⁸ ; Franco Borzio⁹ ; Eugenio Caturelli¹⁰ ; Maria Chiaramonte¹¹ ; Franco Trevisani¹² ; for the Italian Liver Cancer (ITA.LI.CA) Group
• 刊名：Seminars in Oncology
• 出版年：April 2014
• 年：2014
• 卷：41
• 期：2
• 页码：252-258
• 全文大小：173 K

文摘

Cirrhosis-related abnormal liver function is associated with predisposition to hepatocellular carcinoma (HCC). It features in several HCC classification systems and is an HCC prognostic factor. The aim of the present study was to examine the phenotypic tumor differences in HCC patients with normal or abnormal plasma bilirubin levels. A 2,416-patient HCC cohort was studied and dichotomized into normal and abnormal plasma bilirubin groups. Their HCC characteristics were compared for tumor aggressiveness features, namely, blood alpha-fetoprotein (AFP) levels, tumor size, presence of portal vein thrombosis (PVT) and tumor multifocality. In the total cohort, elevated bilirubin levels were associated with higher AFP levels, increased PVT and multifocality, and lower survival, despite similar tumor sizes. When different tumor size terciles were compared, similar results were found, even among patients with small tumors. A multiple logistic regression model for PVT or tumor multifocality showed increased odds ratios for elevated levels of gamma glutamyl transpeptidase (GGTP), bilirubin, and AFP and for larger tumor sizes. We conclude that HCC patients with abnormal bilirubin levels had worse prognosis than patients with normal bilirubin. They also had an increased incidence of PVT and tumor multifocality, and higher AFP levels, in patients with both small and larger tumors. The results show an association between bilirubin levels and indices of HCC aggressiveness.